Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era

被引：4
作者：
Alsoud, Dahham [1 ]
Verstockt, Bram [1 ,2 ]
Vermeire, Severine [1 ,2 ]
机构：
[1] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Translat Res Gastrointestinal Disorders TARGID IB, Leuven, Belgium
[2] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2022年 / 55卷 / 07期
关键词：
D O I：
10.1111/apt.16797
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：885 / 886
页数：2
相关论文
共 9 条
[1]   Breaking the therapeutic ceiling in drug development in ulcerative colitis [J].
Alsoud, Dahham ;
Verstockt, Bram ;
Fiocchi, Claudio ;
Vermeire, Severine .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (07) :S89-S95
[2]   Supratherapeutic Infliximab Levels Do Not Predict Risk of Short-term Complications in Adults With Crohn's Disease [J].
Bhattacharya, Abhik ;
Travis, Daniel ;
Osterman, Mark T. ;
Lewis, James D. ;
Rao, Bhavana Bhagya ;
Lee, Helen ;
Lichtenstein, Gary R. .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2023, 57 (01) :66-73
[3]   A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease [J].
Billiet, Thomas ;
Dreesen, Erwin ;
Cleynen, Isabelle ;
Wollants, Willem-Jan ;
Ferrante, Marc ;
Van Assche, Gert ;
Gils, Ann ;
Vermeire, Severine .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (10) :1438-1445
[4]   Immunogenicity to infliximab is associated with HLA-DRB1 [J].
Billiet, Thomas ;
Vande Casteele, Niels ;
Van Stappen, Thomas ;
Princen, Fred ;
Singh, Sharat ;
Gils, Ann ;
Ferrante, Marc ;
Van Assche, Gert ;
Cleynen, Isabelle ;
Vermeire, Severine .
GUT, 2015, 64 (08) :1344-U196
[5]   Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease [J].
Colman, Ruben J. ;
Xiong, Ye ;
Mizuno, Tomoyuki ;
Hyams, Jeffrey S. ;
Noe, Joshua D. ;
Boyle, Brendan ;
D'Haens, Geert R. ;
van Limbergen, Johan ;
Chun, Kelly ;
Yang, Jane ;
Rosen, Michael J. ;
Denson, Lee A. ;
Vinks, Alexander A. ;
Minar, Phillip .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (05) :593-603
[6]   Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity [J].
Dubinsky, Marla C. ;
Mendiolaza, Michelle L. ;
Phan, Becky L. ;
Moran, Hunter R. ;
Tse, Stacy S. ;
Mould, Diane R. .
INFLAMMATORY BOWEL DISEASES, 2022, 28 (09) :1375-1385
[7]   HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease [J].
Sazonovs, Aleksejs ;
Kennedy, Nicholas A. ;
Moutsianas, Loukas ;
Heap, Graham A. ;
Rice, Daniel L. ;
Reppell, Mark ;
Bewshea, Claire M. ;
Chanchlani, Neil ;
Walker, Gareth J. ;
Perry, Mandy H. ;
McDonald, Timothy J. ;
Lees, Charlie W. ;
Cummings, J. R. Fraser ;
Parkes, Miles ;
Mansfield, John C. ;
Irving, Peter M. ;
Barrett, Jeffrey C. ;
McGovern, Dermot ;
Goodhand, James R. ;
Anderson, Carl A. ;
Ahmad, Tariq .
GASTROENTEROLOGY, 2020, 158 (01) :189-199
[8]   Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease [J].
Schultheiss, Johannes P. D. ;
Mahmoud, Remi ;
Louwers, Jonas M. ;
van der Kaaij, Michiel T. ;
van Hellemondt, Boris P. ;
van Boeckel, Petra G. ;
Mahmmod, Nofel ;
Jharap, Bindia ;
Fidder, Herma H. ;
Oldenburg, Bas .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (10) :1298-1308
[9]   How Do We Predict a Patient's Disease Course and Whether They Will Respond to Specific Treatments? [J].
Verstockt, Bram ;
Parkes, Miles ;
Lee, James C. .
GASTROENTEROLOGY, 2022, 162 (05) :1383-1395
1